Timing may become medicine’s next major frontier

Reflections from SRBR on the future of chronobiology, clinical medicine, and systems-based care.

May 18, 2026

I am an active member of SRBR, and an attendee at the 2026 conference and their dedicated Circadian Medicine Day in Amelia Island, Florida. This is Part II of a two-part series. Read Part I: “The top scientists driving circadian anything.”

In Part I, I introduced you to five scientists whose work is shaping the future of circadian medicine, from translating research into clinical trials to wearable tools and longevity interventions. What I hoped came through in that article was that this is a field that has been doing serious, layered, painstaking work for a very long time.

So when I say that circadian medicine is at an inflection point, I am not saying the science just arrived. I am saying that science has been arriving steadily for 40 years, and that what I witnessed at the 2026 SRBR conference was the field beginning to build the institutional architecture to match what biology has already shown.

What I watched unfold over five days was a field seriously considering a scenario that basic science alone cannot answer: How do we build this into clinical medicine?

Clinicians in attendance were direct about it: to bring circadian medicine into practice, they need overwhelming evidence. Randomized controlled trials. Indisputable proof. That is a high bar, but it is the right bar, and the encouraging news is that the evidence is increasingly clearing it.

What is also becoming clear is that the gap between the science and clinical adoption is no longer primarily a data problem. It is:

an infrastructure problem
a training problem
a language problem
a collaboration problem

And perhaps most of all, a silo problem. The same one that has kept too many good ideas trapped within the disciplines that generated them, never quite reaching the patients who need them.

The Evidence Is No Longer the Barrier

The common assumption that circadian medicine is still emerging, still preliminary, still “promising” is no longer accurate across the board.

Consider what Francis Levi, of the University of Paris-Saclay, presented at the conference. Across 38 retrospective studies and one randomized trial published between 2021 and 2026, involving more than 10,000 cancer patients over three continents and eleven cancer types, the timing of immunotherapy treatments consistently appeared to matter. Morning administration was associated with a risk ratio of 0.55 for earlier death, while the first randomized trial reported an even stronger effect at 0.42.

In practical terms, patients receiving immunotherapy earlier in the day experienced nearly half the risk of earlier mortality compared to those treated later. What is particularly notable is that this signal has now appeared across multiple cancer types and populations, suggesting timing may influence treatment response more than previously recognized. Eleven additional randomized trials are currently underway to determine whether these effects hold across broader clinical settings and cancer populations.

The slide Levi showed carried a subtitle that should stop any administrator or payer in their tracks: “Chronotherapy for Improving Survival at No Cost.” Not a new drug or device. No referrals or additional appointments. Just a different time on the infusion schedule.

Consider the behavioral evidence. The largest impact on circadian health doesn’t come from pharmaceutical interventions or sophisticated monitoring technology. It comes from regularity: consistent meal timing windows, consistent sleep-wake schedules, consistent light exposure. The clock, it turns out, rewards consistency above almost everything else. This is not complicated science. It is almost embarrassingly simple advice that the healthcare system has not found a way to systematically deliver.

I don’t believe evidence is the barrier. The barrier is the infrastructure of traditional medicine across clinical, institutional, educational, and financial tenets. The barrier is a medical system built around the ‘what’ of disease, not the ‘when’. And the barrier is a set of disciplinary silos that have grown independently, without whole-person health in mind.

The Infrastructure Is (Finally) Being Considered

At Amelia Island, the leaders of this field were not just presenting research. They were also doing institution-building.

The International Association of Circadian Health Clinics (IACHC) presented its mission and its founding working group to the assembled community. The founding roster spans virtually every major clinically oriented circadian researcher worldwide: Czeisler, Scheer, Klerman, Zee, Boivin, Rajaratnam, Kramer, and more than a dozen others. Their stated goals include:

Develop clinical guidelines
Establish screening tools
Educate health professionals
Influence funding priorities

Their first annual conference was held in 2025, and the committee is gearing up for round two, which will take place in Tokyo this November. The theme is titled “Advancing Clinical Practice: Integrating Circadian Medicine into Patient Care and Treatment.”

The local organizing committee includes leading Japanese chronobiologists and, notably, Masashi Yanagisawa, the discoverer of orexin (one of the brain’s “stay awake and stay engaged” signaling systems), whose entry into the circadian medicine conversation signals an important convergence between sleep science and circadian biology.

The roadmap panel at SRBR this year, chaired by Steven Shea, included notables like John Hogenesch, Phyllis Zee, Joe Bass, and Francis Levi, who laid out the specific problems that need solving:

independent accreditation boards for each country
training curricula that introduce circadian health earlier in medical education
clinical practice models across behavioral, pharmacological, and occupational settings
reimbursement and funding structures
frameworks that account for how practice will vary across healthcare systems and cultures.

In Europe, the Circamed initiative has articulated a five-action framework — Align, Decode, Reveal, Empower, Inspire — covering everything from treatment timing in patients to biomarker development to regulatory infrastructure to public education.

This is serious, coordinated, international infrastructure work. It deserves to be recognized as such.

And yet there are real, unsolved problems that the field has been honest about. Actigraphy and dim-light melatonin onset testing are not easy to implement across diverse patient populations.

The self-administered biomarker that could tell a clinician or patient where someone’s biological clock sits right now, readable from saliva, blood, or urine, based on RNA expression, DNA methylation, or protein levels, doesn’t yet exist in clinically validated form.

The field doesn’t yet have a firm consensus on two foundational clinical questions: How much circadian misalignment is too much? And how much dampening of circadian amplitude becomes clinically significant? Without quantitative thresholds, clinical decision-making remains more art than protocol.

These are real gaps being addressed, but they won’t close on their own, and they won’t close quickly if circadian medicine remains a niche interest of a specialized research community rather than a recognized dimension of clinical practice.

The Partnership That’s Been Waiting Right There

Here is the argument I want to make, as someone who sat in those sessions and watched this field wrestle with how to get its knowledge into clinical practice:

The infrastructure you’re trying to build already exists in part. It’s called Lifestyle Medicine.

Lifestyle medicine has, over the past decade, done something remarkable: it has taken a set of evidence-based behavioral interventions (nutrition, physical activity, restorative sleep, stress management, substance avoidance, and social connection) and built a clinical discipline around them.

Board certification, fellowship training programs, clinical practice guidelines, international societies, and a growing base of clinicians in primary care, internal medicine, cardiology, and beyond who are already asking their patients about sleep, diet, and daily routine.

Restorative sleep is already one of the six pillars of lifestyle medicine. The field already frames sleep not as a symptom to be treated but as a primary health behavior to be optimized.

Chronotype assessment, meal timing guidance, light hygiene, and circadian-aligned scheduling are natural extensions of what lifestyle medicine practitioners are already doing, or already trying to do, without the mechanistic framework that circadian science provides.

There are lifestyle medicine clinics operating around the world that are already implementing circadian-adjacent practices without the formal circadian medicine vocabulary or infrastructure to support them. They are asking patients when they eat. They are talking about sleep regularity. They are counseling on evening light exposure.

This represents an extraordinary opportunity and perhaps a cautionary tale about what happens when fields don’t talk to each other.

Because the inverse is also true: lifestyle medicine, for all its strengths, often lacks the mechanistic depth that circadian biology provides. It knows that sleep timing matters. Circadian medicine knows why, and increasingly how much, and for whom, and by what biological pathway.

The partnership between these two fields could be genuinely synergistic, rare in medicine, in which one field provides the clinical infrastructure and patient relationships, and the other provides the biological specificity and measurement tools.

The patient who walks into a lifestyle medicine clinic with metabolic syndrome, poor sleep, and irregular eating patterns is already the patient that circadian medicine is designed to help.

The Myopia We Can’t Afford

This is the larger problem, and it extends well beyond the circadian medicine-lifestyle medicine interface.

We have built modern medicine into a collection of increasingly narrow specialties, each with its own journals, conferences, funding streams, training pipelines, and clinical fiefdoms. This structure has produced an extraordinary depth of knowledge across domains. It has also produced a healthcare system that is structurally incapable of seeing the whole person, which pays the price in outcomes, costs, and the frustration of patients who see six specialists and come away with six different answers that are not integrated.

Circadian medicine, by its very nature, cuts across medical silos. The circadian clock is not a cardiology, neurology, or endocrinology phenomenon. It is a fundamental property of human biology that affects every system simultaneously. The morning peak in cardiac events, the circadian regulation of insulin sensitivity, the timing of the immune response that determines vaccine response, the clock-dependent efficacy of chemotherapy, the role of circadian disruption in Alzheimer’s pathology, and the mood-stabilizing effects of light therapy in psychiatry are the same story, told by different specialists.

The IACHC’s founding working group includes cardiologists, sleep physicians, neurologists, endocrinologists, psychiatrists, and public health researchers. The SRBR roadmap panel included not just chronobiologists but a practicing cardiologist. The clinical tracks at the 2026 SRBR covered cardiovascular medicine, neurology, psychiatry, oncology, pulmonology, endocrinology, and hypertension in a single day.

This cross-disciplinary reach is not accidental; it reflects an understanding that the clinical home for circadian medicine cannot be a single specialty, because the biology doesn’t respect specialty boundaries.

But understanding it doesn’t automatically produce the cross-disciplinary training, shared clinical protocols, integrated electronic health records, or joint funding mechanisms that would make whole-person circadian care possible in practice. Those require deliberate institutional choices that medicine has historically been slow to make.

The patients who stand to benefit most from circadian medicine are not, for the most part, people seeking boutique wellness services. They are shift workers, such as nurses, paramedics, factory workers, and long-haul drivers, whose circadian systems are chronically disrupted by the economy’s demand for 24-hour operations.

They are people with metabolic syndrome who eat within a twelve-hour window that starts at noon and ends at midnight, unaware that moving that window earlier and narrowing it could change their metabolic trajectory without changing a single calorie. They are cancer patients whose treatment timing is still being set by scheduling convenience rather than biological optimization. They are elderly patients whose circadian amplitude is declining, taking them steadily toward metabolic dysfunction, immune senescence, and cognitive decline, with no clinical system watching the clock on their behalf.

What “It’s About Time” Actually Means

The phrase keeps coming up in circadian medicine — it’s about time — as both pun and argument. It is about time in the literal sense: the biological dimension of rhythm organization that medicine must integrate. And it is about time in the colloquial sense: this has been delayed long enough.

The infrastructure is being built. The evidence, in key domains, is ready. The clinical partnerships with lifestyle medicine, with preventive medicine, with integrative health are there to be made.

What remains is will: the willingness of medical educators, clinical leaders, health systems, and payers to recognize that timing is not a curiosity or a fringe concern, but a fundamental parameter of human health that belongs in every clinical encounter.

Discussion about this post

Ready for more?